Spiegel Allen M
Albert Einstein College of Medicine, Belfer 312, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
Trans Am Clin Climatol Assoc. 2013;124:94-110.
The development of human embryonic stem cell (hESC) lines in 1998 offered the prospect of a new era of regenerative medicine in which cell therapy might cure intractable diseases such as type 1 diabetes, Parkinson's disease, and spinal cord injury. The Bush Administration decision in 2001 to restrict federal funding of hESC research touched off a controversy that continues to the present. One response to the Bush policy was establishment of state stem cell research funding programs, notably the California Institute of Regenerative Medicine (CIRM). As Director of the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) and Vice Chair of the National Institutes of Health (NIH) Stem Cell Task Force, and now as a member of the Empire State Stem Cell Funding Board and member of an Institute of Medicine (IOM) committee charged with evaluation of the CIRM, I have had the opportunity to gain a first-hand perspective of the field. Here I present my impressions of the legal and science policy debates and selectively summarize research progress toward the hoped-for cures.
1998年人类胚胎干细胞（hESC）系的发展为再生医学的新纪元带来了希望，在这个新纪元里，细胞疗法或许能够治愈诸如1型糖尿病、帕金森病和脊髓损伤等疑难病症。2001年布什政府决定限制对hESC研究的联邦资金投入，引发了一场持续至今的争议。对布什政策的一种回应是建立州干细胞研究资金项目，尤其是加利福尼亚再生医学研究所（CIRM）。作为国立糖尿病、消化和肾脏疾病研究所（NIDDK）所长以及国立卫生研究院（NIH）干细胞特别工作组副主席，现在又作为帝国州干细胞资金委员会成员以及负责评估CIRM的医学研究所（IOM）委员会成员，我有机会对该领域有了第一手的认识。在此，我阐述一下我对法律和科学政策辩论的看法，并选择性地总结一下在实现所期望的治愈方法方面的研究进展。
